Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: Results of the Japan infant leukaemia study (MLL96)

British Journal of Haematology

Volumn 118, Issue 4, 2002, Pages 999-1010

  Isoyama, Keiichi ^a   Eguchi, Mariko ^b   Hibi, Shigeyoshi ^c   Kinukawa, Naoko ^d   Ohkawa, Hiroji ^e   Kawasaki, Hajime ^f   Kosaka, Yoshiyuki ^g   Oda, Takanori ^h   Oda, Megumi ⁱ   Okamura, Takayuki ^j   Nishimura, Shin Ichiro ^k   Hayashi, Yasuhide ^l   Mori, Taijiro ^m   Imaizumi, Masue ⁿ   Mizutani, Shuki ^e   Tsukimoto, Ichiro ^o   Kamada, Nanao ^b   Ishii, Eiichi ^p  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KOBE UNIVERSITY   (Japan)

^h SAPPORO MEDICAL UNIVERSITY   (Japan)

ⁱ OKAYAMA UNIVERSITY   (Japan)

^j RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^k HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^l UNIVERSITY OF TOKYO   (Japan)

^m KEIO UNIVERSITY   (Japan)

ⁿ TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o TOHO UNIVERSITY   (Japan)

^p SAGA UNIVERSITY   (Japan)

more..

Author keywords

Childhood leukaemia; CNS leukaemia; Haematopoietic stem cell transplantation; Infants; Intensive chemotherapy; MLL gene rearrangement

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PIRARUBICIN; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE; GENETIC ANALYSIS; GENETIC DISORDER; GENOTOXICITY; HAZARD ASSESSMENT; HIGH RISK POPULATION; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MALE; MLL GENE; NEWBORN; PRIORITY JOURNAL; REMISSION; RISK; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FOLLOW-UP STUDIES; GENE REARRANGEMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; JAPAN; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PATIENT SELECTION; PROTO-ONCOGENES; REMISSION INDUCTION; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TRANSCRIPTION FACTORS;

EID: 18544376033     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03754.x     Document Type: Article

References (42)

1. Detection of residual host cells in sex-mismatched bone marrow transplantation in various hematological diseases by fluorescence in situ hybridization
2. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
3. The role of immunophenotype in acute lymphoblastic leukemia of infant age
4. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age
5. Sequence-independent amplification and labeling of yeast artificial chromosomes for fluorescence in situ hybridization
6. Acute lymphoblastic leukemia of infancy: Results in five multicentric therapy studies ALL BFM 1970-86
7. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome
8. Acute lymphoblastic leukaemia in infancy: Experience in MRC UKALL trials
9. Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(p21;q23), t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations
10. Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias
11. Regression models and life tables
12. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
13. Treatment of infant leukemia with busulfan, cyclophosphamide + etoposide and bone marrow transplantation
14. Improved survival for acute lymphoblastic leukaemia in infancy: The experience of EORTC-childhood leukaemia cooperative group
15. Infant leukemia biology, aetiology and treatment
16. Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: Impact of the 11q23 breakpoint on outcome: A report of the Children's Cancer Group
17. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4;11)(q21;q23)
18. Infant leukemia in Japan: Clinical and biological analysis of 48 cases
19. Clinical and biological aspects of acute lymphoblastic leukemia in 62 infants: Retrospective analysis of the Tokyo Children's Cancer Study Group
20. Non-parametric estimation from incomplete observation
21. High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support
22. Detection of 11q23/MLL rearrangements in infant leukemias with fluorescence in situ hybridization and molecular analysis
23. Comparison of cytogenetics, Southern blotting, and fluorescence in situ hybridization as methods for detecting MLL gene rearrangements in children with acute leukemia and with 11q23 abnormalities
24. Treatment of infant acute lymphoblastic leukemia in Japan
25. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - Implication for treatment of infants
26. Selecting treatment for children with acute lymphoblastic leukemia
27. Total body irradiation, cyclophosphamide, and etoposide with stem cell transplant as treatment for infants with acute lymphocytic leukemia
28. Acute lymphoblastic leukemia
29. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia
30. Acute lymphoblastic leukemia in infants less than one year of age: A cumulative experience of the Children's Cancer Study Group
31. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy
32. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group
33. MLL rearrangements in infant leukemia: Is there a higher frequency in female?
34. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: A pediatric Oncology Group Study
35. 11q23 rearrangements in acute leukemia
36. Intensified therapy for infants with acute lymphoblastic leukemia
37. Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia
38. -AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation
39. Gene rearrangement and truncated mRNA in cell lines with 11q23 translocation
40. Identification of a gene. MLL, that spans the breakpoint in 11q23 translocation associated with human leukemias